1 in 41 people in the U.S. is infected with the new crown
Daily economic news
10-17 09:32
An average of 1 in 41 people in the United States is infected with the new crown. Pfizer plans to apply for an emergency vaccine authorization in November. The WHO says that dexamethasone is still the only effective drug for treating severely ill
According to the latest news from CCTV News, there are more than 8.03 million confirmed cases of new coronary pneumonia in the United States, which means that on average, 1 in 41 Americans is infected with the new crown virus. The US population accounts for about 4% of the world’s total population, but the cumulative number of confirmed cases accounts for more than 20% of the world’s total cumulative cases. Many U.S. experts have recently warned frequently that the United States has entered a colder winter at the current level of the epidemic, and “the prospects are not good.”
American documentary film “Full Control”
“The U.S. government has not done its best to deal with the epidemic”; “Scientists are ringing the alarm every day, but the U.S. government has done nothing”; “The truth is disgusting”… According to US media reports, Oscar-winning director Alex ·The documentary “Full Control” directed by Gibney and others was released recently. The film pointed out that from the emergence of the first known case in Washington State, the US government’s misjudgment, missed opportunities and hasty response began.
1 in 41 people in the U.S. is infected
WHO: Dexamethasone is still the only effective drug for severely ill patients with new coronary pneumonia, and remdesivir is almost ineffective
On October 16, local time, WHO held a routine press conference for new coronary pneumonia. WHO Director-General Tan Desai said that the mid-term results of the “solidarity trial” showed that remdesivir, hydroxychloroquine, and lopinavir Tonavir and interferon treatments have little effect in preventing deaths or shortening the length of hospitalization in patients with new coronary pneumonia. The “Unity Trial” will evaluate other therapies, including monoclonal antibodies and new antiviral drugs. At present, dexamethasone is still the only effective drug for severe patients with new coronary pneumonia.
